Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | FLT4 | P35916 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7140183 | 0.81 | CYP1A2 (0.44) | CYP3A4CYP2D6ALDH1A1PGR | |
| SCHEMBL3247012 | 0.81 | ALDH1A1 (0.50) | SOD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17376536 | 0.75 | EPAS1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8745524 | 0.75 | SOD1 (0.50) | SOD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL11158255 | 0.75 | ALDH1A1 (0.43) | CYP3A4FLT1FLT4KDRCYP2D6 | |
| SCHEMBL17730411 | 0.73 | FNTA (0.41) | CYP3A4TSHRALDH1A1 | |
| SCHEMBL3250089 | 0.73 | ALDH1A1 (0.45) | TSHRALDH1A1MAPK1 | |
| SCHEMBL878654 | 0.73 | SOD1 (0.48) | SOD1FABP4TSHRALDH1A1ACLY | |
| SCHEMBL17376376 | 0.71 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21995280 | 0.71 | GAA (0.43) | FLT1FLT4KDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908846-B2 | Composition, synthesis, and use of new arylsulfonyl isonitriles | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-03-06 | — | — | US | disclosed |
| US-20150239833-A1 | COMPOSITION, SYNTHESIS, AND USE OF NEW ARYLSULFONYL ISONITRILES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2015-08-27 | — | — | US | disclosed |
| EP-1575575-B1 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | disclosed |
| US-6875771-B2 | Pyridopyrimidine derivatives as 5-HT6 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
| US-20040019064-A1 | Pyridopyrimidine derivatives as 5-HT6 antagonists | WU YONG-JIN (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019064-A1 | Pyridopyrimidine derivatives as 5-HT6 antagonists | HTR6, HTR4, HTR1A | SOD1 1931/4885PSEN1 143/4885PSEN2 93/4885 |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | SOD1 1798/4885PSEN1 3650/4885PSEN2 2643/4885 |
| US-20150239833-A1 | COMPOSITION, SYNTHESIS, AND USE OF NEW ARYLSULFONYL ISONITRILES | SRMS, AADAC, CYP3A4 | SOD1 2561/4885PSEN1 1862/4885PSEN2 1682/4885 |
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | SOD1 1247/4885PSEN1 3677/4885PSEN2 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.